Hot Investor Mandate: USA-Based Investment Firm Makes Both Venture & Growth Stage Investments, Focusing Exclusively on Therapeutics

17 Aug

Frazier Healthcare Ventures was founded in 1991 and is based in Seattle, WA.  The firm has $2.2 billion of assets under management, and closed a new $525 million fund in 2016.  Frazier currently has two investment strategies; growth-stage investments in healthcare and pharma service providers (these investments focus on companies with $5-30m EBITDA), and venture-stage investments in life science companies.  Frazier’s venture allocations have initial sizes of $5m or higher, with the potential for allocations of up to $20m over the life of an investment.  While Frazier primarily invests in companies based in or with significant operations in the USA and/or Canada, the firm will also consider opportunities in Europe.  In addition to growth and venture-stage investments, Frazier also engages in company creation.  The firm is a lead investor in most of its deals.

Frazier Life Sciences only invests in therapeutics, with a focus on asset-based companies. Frazier typically prefers to invest in companies with products which are 6-18 months away from bringing a product candidate into Phase I clinical trials, but may consider investing in assets that are earlier or later than that. The firm invests in all therapeutic areas and all modalities.

Frazier Healthcare Ventures has no fixed requirements for companies or management teams, but looks for strong teams that lead companies that can make use of over $10m in capital; companies with smaller capital needs are not of interest. Frazier can invest in both privately-held and public life science companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment